Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management
Anna Chang, Susan H. Fox
Drugs (2016) Vol. 76, Iss. 11, pp. 1093-1118
Closed Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

Management of common adverse effects of antipsychotic medications
T. Scott Stroup, Noel‐Marie Gray
World Psychiatry (2018) Vol. 17, Iss. 3, pp. 341-356
Open Access | Times Cited: 444
Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors
Stephen M. Stahl
CNS Spectrums (2016) Vol. 21, Iss. 4, pp. 271-275
Open Access | Times Cited: 219
Parkinson’s Disease Psychosis: Presentation, Diagnosis and Management
Ruth B. Schneider, Julia Iourinets, Irene Hegeman Richard
Neurodegenerative Disease Management (2017) Vol. 7, Iss. 6, pp. 365-376
Closed Access | Times Cited: 159
Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases
Nicola Warren, Cullen O’Gorman, Alexander Lehn, et al.
Journal of Neurology Neurosurgery & Psychiatry (2017) Vol. 88, Iss. 12, pp. 1060-1064
Closed Access | Times Cited: 151
Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease
Roberta Balestrino, Pablo Martínez‐Martin
Journal of the Neurological Sciences (2016) Vol. 373, pp. 173-178
Closed Access | Times Cited: 122
Minor hallucinations in Parkinson disease
Abhishek Lenka, Javier Pagonabarraga, Pramod Kumar Pal, et al.
Neurology (2019) Vol. 93, Iss. 6, pp. 259-266
Open Access | Times Cited: 93
Neuroprotective effects of Danshensu on rotenone-induced Parkinson’s disease models in vitro and in vivo
Tian Wang, Cuiting Li, Bing Han, et al.
BMC Complementary Medicine and Therapies (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 89
Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases
Esra Küpeli Akkol, İrem Tatlı Çankaya, Gökçe Şeker Karatoprak, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 87
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giuseppe Di Giovanni, Dubravka Švob Štrac, Montse Solé, et al.
Frontiers in Neuroscience (2016) Vol. 10
Open Access | Times Cited: 58
Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome
Stephen M. Stahl
CNS Spectrums (2016) Vol. 21, Iss. 5, pp. 355-359
Open Access | Times Cited: 52
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
Robert A. Hauser, Rajesh Pahwa, Caroline M. Tanner, et al.
Journal of Parkinson s Disease (2017) Vol. 7, Iss. 3, pp. 511-522
Open Access | Times Cited: 49
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders
K. A. Jellinger
Journal of Neural Transmission (2019) Vol. 126, Iss. 8, pp. 933-995
Closed Access | Times Cited: 43
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis
Fernando Pagán, Paul E. Schulz, Yasar Torres‐Yaghi, et al.
CNS Drugs (2024) Vol. 38, Iss. 5, pp. 333-347
Open Access | Times Cited: 5
Evidence for the use of cannabinoids in Parkinson’s disease
Carsten Buhmann, Tina Mainka, Georg Ebersbach, et al.
Journal of Neural Transmission (2019) Vol. 126, Iss. 7, pp. 913-924
Closed Access | Times Cited: 37
Potential Risk Factors for Psychosis in Parkinson’s Disease: A Review of Cohort and Case-Control Studies
Dimitry S. Davydow, Michael S. Okun, Gregory M. Pontone
Journal of Geriatric Psychiatry and Neurology (2025)
Closed Access
Treatment of psychotic symptoms in patients with Parkinson disease
Jack J. Chen
Mental Health Clinician (2017) Vol. 7, Iss. 6, pp. 262-270
Open Access | Times Cited: 39
Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update
Philippe Huot, Véronique Sgambato‐Faure, Susan H. Fox, et al.
ACS Chemical Neuroscience (2017) Vol. 8, Iss. 5, pp. 973-986
Closed Access | Times Cited: 38
The efficacy of apomorphine – A non-motor perspective
Miguel Rosa-Grilo, Mubasher A. Qamar, Andrew Evans, et al.
Parkinsonism & Related Disorders (2016) Vol. 33, pp. S28-S35
Open Access | Times Cited: 35
Pathology of behavior in PD: What is known and what is not?
Kaylena A. Ehgoetz Martens, Simon J.G. Lewis
Journal of the Neurological Sciences (2016) Vol. 374, pp. 9-16
Open Access | Times Cited: 34
Evidence-Based Review of Pharmacotherapy Used for Parkinson’s Disease Psychosis
Kyle John Wilby, Eric Johnson, Hannah E. Johnson, et al.
Annals of Pharmacotherapy (2017) Vol. 51, Iss. 8, pp. 682-695
Closed Access | Times Cited: 34
Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
Amanda Kitten, Sarah A Hallowell, Stephen R. Saklad, et al.
Innovations in clinical neuroscience (2018) Vol. 15, pp. 16-22
Closed Access | Times Cited: 34
Serotonergic targets for the treatment of l-DOPA-induced dyskinesia
Kathryn Lanza, Christopher Bishop
Journal of Neural Transmission (2018) Vol. 125, Iss. 8, pp. 1203-1216
Closed Access | Times Cited: 33
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
Caroline M. Tanner, Rajesh Pahwa, Robert A. Hauser, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 2, pp. 543-558
Open Access | Times Cited: 30
Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
Jamir Pitton Rissardo, Ícaro Durante, Idan Sharon, et al.
Brain Sciences (2022) Vol. 12, Iss. 10, pp. 1286-1286
Open Access | Times Cited: 18
Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium
Christine Daniels, J. Muñoz, Elisabeth Jentschke, et al.
Neurological Research and Practice (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top